GlassScriptPhysician profile
Fadi A El Atat
NPI 1386776797
$7,631.90
in general payments reported to CMS, 2019-2025
44 companies · $572 in 2025
The $572 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,447 · 2020: $971 · 2021: $1,207 · 2022: $1,234 · 2023: $1,329 · 2024: $873 · 2025: $572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,768 · Education: $5.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.94 |
| Education | $5.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,192.46 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Glaxosmithkline, LLC. | $866.72 | 2019-2023 | Trelegy Ellipta |
| Novo Nordisk INC | $770.66 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $545.04 | 2019-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $527.45 | 2019-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $477.13 | 2019-2025 | |
| Amgen INC. | $370.78 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $343.99 | 2019-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $253.87 | 2021-2025 | |
| Amarin Pharma, INC. | $159.55 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $138.14 | 2019-2023 | Xarelto |
| Horizon Therapeutics Plc | $81.85 | 2019-2022 | |
| Pfizer INC. | $75.41 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $75.00 | 2024-2025 | Gvoke Hypopen |
| Boston Scientific Corporation | $74.96 | 2022-2025 | Cds - Mct/Cem Monitoring, Watchman Flx |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $68.50 | 2019-2021 | |
| Esperion Therapeutics, INC. | $57.13 | 2020-2024 | Nexletol |
| Ironwood Pharmaceuticals, INC | $44.89 | 2019-2020 | |
| Mannkind Corporation | $41.50 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $37.00 | 2019 | |
| Abbott Laboratories | $29.75 | 2021-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $27.49 | 2022-2023 | Livalo, Seglentis |
| Alnylam Pharmaceuticals INC. | $26.87 | 2023 | Onpattro |
| Kiniksa Pharmaceuticals International, Plc | $26.84 | 2024 | Arcalyst |
| E.R. Squibb & Sons, L.L.C. | $25.56 | 2019-2020 | |
| G Medical Diagnostic Services, INC. | $24.67 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $24.67 | 2019 | |
| Shockwave Medical, INC | $23.21 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Lexicon Pharmaceuticals, INC. | $17.17 | 2023 | Inpefa |
| Supernus Pharmaceuticals, INC. | $16.59 | 2019 | |
| United Therapeutics Corporation | $15.86 | 2023 | Tyvaso |
| Exact Sciences Corporation | $15.48 | 2025 | The Cologuard Plus Collection Kit |
| Acadia Pharmaceuticals INC | $15.46 | 2024 | Nuplazid |
| Dexcom, INC. | $15.00 | 2021 | |
| Intra-Sana Laboratories | $14.43 | 2024 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Abiomed | $13.85 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $13.62 | 2023 | Arcalyst |
| Tactile Systems Technology INC | $13.54 | 2024 | Flexitouch Plus, Entre Plus |
| Cashflow Solutions, LLC | $12.76 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Mylan Specialty L.P. | $12.69 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.50 | 2020 | |
| Hikma Pharmaceuticals USA | $12.01 | 2022 | |
| Redhill Biopharma INC. | $11.35 | 2021 | |
| Zoll Circulation INC | $8.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fadi El Atat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.